Immunology / Virology & Vaccines

Vaccine
#AstraZeneca #Bioconjugates #Immunology / Virology & Vaccines #Mergers and acquisitions

AstraZeneca buys conjugate vaccine developer Omniose

Omniose is to be acquired by AstraZeneca, following a productive three-year exclusive research collaboration between the two companies.  Under the terms of the agreement, Omniose has become a wholly owned subsidiary of AstraZeneca and a part of the Infectious Disease Unit.   The acquisition brings Omniose’s… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Immunology / Virology & Vaccines #NEC Bio #Pandemic response

EU project strengthens pandemic preparedness with AI vaccine design

PREPAIR VAC is a Horizon Europe-funded research project aimed at strengthening pandemic preparedness through the application of artificial intelligence (AI) in vaccine design.  NEC Corporation’s NEC OncoImmunity (NOI) will be working alongside several European partners comprising a research consortium.  The four-year research grant beginning in… Read More

#News

mRNA
#Drug discovery #eBook #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines

Discover mRNA: Beyond vaccines to personalised medicine

Despite a challenging funding landscape, 2026 has seen two groundbreaking advances in mRNA vaccine discovery; the first-ever mRNA seasonal influenza vaccine for adults and the first positive Phase III readout for an mRNA-based cancer therapy. This eBook explores how the mRNA platform has evolved since its use in Covid-19 vaccines,… Read More

#News

#ENA Respiratory #Immunology / Virology & Vaccines #Phase II trial #Respiratory

Community study tests respiratory protective nasal spray

ENA Respiratory has dosed the first participants in Part B of its Phase IIa community study of INNA-051, a virus-agnostic, dry powder nasal spray.  INNA-051 is designed to prime the natural antiviral host defences in the nose where common respiratory viruses like rhinovirus, flu, RSV and coronaviruses… Read More

#News

RNA vaccine
#Immunology / Virology & Vaccines #Influenza #mRNA #mRNA-based vaccines

mRNA vaccine produces more diversified antibody response

A new study has revealed how an mRNA-based influenza vaccine reshapes immune responses at the cellular and molecular levels.   By tracking germinal-centre (GC) activity and individual secreted antibody clonotypes for up to six months, researchers uncovered how vaccination drives the evolution and diversification of immune responses.  … Read More

#News

Flu vaccine
#GSK #Immunology / Virology & Vaccines #Influenza #mRNA #mRNA-based vaccines

GSK reveals plans to advance mRNA flu vaccine to Phase III

GSK has revealed that its mRNA seasonal influenza (flu) vaccine candidate has shown higher immune responses against all influenza strains tested compared to licensed standard dose and high dose inactivated flu vaccines.  The Phase II data were presented at the OPTIONS XIII Conference for the Control of… Read More

#News

Close up of vaccine syringe
#CEPI #Ebola virus #Immunology / Virology & Vaccines #Outbreak

CEPI backs Minapharm’s Bundibugyo ebolavirus vaccine candidate

African biopharmaceutical company Minapharm Group will receive up to $16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate.  The investment is part of efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on… Read More

#News #Trending News

Patient receiving vaccine
#Immunology / Virology & Vaccines #National Institute for Health Research #Phase I trial #Stablepharma #Vaccines

Fridge-free vaccine effective at 30°C for at least two years

The world-first trial of a fridge-free tetanus-diphtheria vaccine has produced encouraging results that could improve access worldwide to crucial treatments.   Around half of vaccines are wasted globally each year, according to the World Health Organization, because of temperature changes during storage and transport.  Fridge-free vaccines… Read More

#News #Trending News

Ebola outbreak
#CEPI #Ebola virus #Immunology / Virology & Vaccines #Moderna #Outbreak

Phase I trial “a major step forward” against Ebola outbreak

Following Health Canada’s authorisation, the first participants have been vaccinated in Moderna’s Phase I clinical study evaluating mRNA-1469, an mRNA vaccine to prevent Bundibugyo ebolavirus (BDBV).  “Vaccinating the first participants with mRNA-1469 marks an important milestone in advancing a vaccine candidate against Bundibugyo ebolavirus, for which no… Read More

#Editor's Choice #News #Trending News

Norovirus
#Antivirals #Cocrystal Pharma #Immunology / Virology & Vaccines #Investment

$5 million private placement supports norovirus programme

Antiviral therapeutics company Cocrystal Pharma has announced a $5 million investment from OPKO Health, a longtime investor in the company.  The investment will support Cocrystal as it advances its lead norovirus programme towards Phase Ib topline data later this year. Under the terms of the agreement,… Read More

#Business & Investment #News

Vaccine vial and syringe
#Drug discovery #eBook #Immunology / Virology & Vaccines

eBook: The latest developments in vaccines and virology 

The 2025 Global Vaccines Market Report from the World Health Organization (WHO) reports a total financial value of $66 billion in 2024, though this is predicted to grow to $227.89 billion by 2034 due to the rising prevalence of infectious diseases and increasing demand for immunisation programmes. Read More

#News

#Clinical trial #DDII #Drug discovery #Immunology / Virology & Vaccines #Lung disease #Monoclonal antibodies #Psilocybin #UK

DDW Highlights: 14 July 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a nanoparticle vaccine showed potential to protect from a ‘tripledemic’. Elsewhere, could… Read More

#Podcasts

Influenza
#Covid-19 #Flu #Immunology / Virology & Vaccines #Respiratory #University of Buffalo

Nanoparticle vaccine shows potential against ‘tripledemic’

A single-shot vaccine under development at the University at Buffalo in the US could protect against flu, Covid-19 and respiratory syncytial virus (RSV) simultaneously.   In a study published in Science Advances, the researchers found that their three-in-one vaccine triggered protective immunity against all three respiratory… Read More

#Editor's Choice #News

Ovarian cancer cells
#Clinical trial #Immunology / Virology & Vaccines #Mayo Clinic #Ovarian cancer

Ovarian cancer vaccine with 40% survival rate to be advanced 

A new agreement is set to advance a vaccine for ovarian cancer which has shown 40% cancer-free survival rates.  Biotechnology company CellxLife has entered an agreement with Mayo Clinic for the dendritic cell vaccine, which reported the 40% 10-year cancer-free survival rate in a Phase I Mayo Clinic study… Read More

#Business & Investment #Cancer Research #News

Vaccine
#Covid-19 #Immunology / Virology & Vaccines #University of Cambridge

‘Universal’ vaccine could protect from several viruses at once 

A novel ‘universal’ vaccine has been engineered to provide protection from thousands of variants in one single dose.  Results from a first-in-human clinical trial, published in the Journal of Infection, show the vaccine protected participants from multiple Sarbeco coronaviruses, a large group of viruses including SARS-CoV-2, as… Read More

#News